Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9570635 | 0.85 | MAPT (0.53) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL8228771 | 0.82 | CA2 (0.63) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL13846717 | 0.82 | CA2 (0.47) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL4089575 | 0.79 | MAPT (0.50) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL9570555 | 0.78 | CA2 (0.48) | CA2PPARGMAPTFFAR1 | |
| SCHEMBL13846806 | 0.77 | CA2 (0.47) | CA2PPARGMAPTKCNH2FFAR1 | |
| SCHEMBL13846779 | 0.77 | MAOA (0.59) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL8172885 | 0.76 | AKT1 (0.53) | MAOACISD1CA2PPARGMAPT | |
| SCHEMBL13846741 | 0.76 | PPARG (0.51) | ALDH1A1CA2PPARGMAPTFFAR1 | |
| SCHEMBL8715367 | 0.76 | FFAR1 (0.51) | MAOBCA2PPARGMAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| WO-2000018746-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | ALDH1A1 4836/4885NPSR1 2544/4885MAOA 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.